Topical Treatments for Dry Eye Disease

Policy # 00640
Original Effective Date: 01/01/2019
Current Effective Date: 08/14/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Verkazia®‡ (cyclosporine ophthalmic emulsion) is addressed separately in medical policy 00802.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider Restasis®‡ (cyclosporine ophthalmic emulsion), cyclosporine ophthalmic emulsion, Restasis Multidose™‡ (cyclosporine ophthalmic emulsion), Cequa™‡ (cyclosporine ophthalmic solution), and Tyrvaya™‡ (varenicline nasal spray) to be eligible for coverage** when the patient selection criteria are met.

Patient Selection Criteria
Coverage eligibility for Restasis (cyclosporine ophthalmic emulsion), cyclosporine ophthalmic emulsion, Restasis Multidose (cyclosporine ophthalmic emulsion), Cequa (cyclosporine ophthalmic solution), and Tyrvaya (varenicline nasal spray) will be considered when the following criteria are met for the requested drug:

• Requested drug is Restasis, generic cyclosporine ophthalmic emulsion, Restasis Multidose, or Cequa:
  o Requested drug will NOT be used in combination with Xiidra®‡ (lifitegrast ophthalmic); AND
  o Patient has one of the following conditions:
    ▪ Dry eye condition due to ocular inflammation associated with keratoconjunctivitis sicca (KCS); OR
Topical Treatments for Dry Eye Disease

Policy #  00640
Original Effective Date:  01/01/2019
Current Effective Date:  08/14/2023

- Dry eye condition due to systemic inflammatory diseases (e.g. Sjögren syndrome, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE]); OR
- Dry eye condition due to ocular surface diseases (e.g., ocular rosacea, atopic keratoconjunctivitis, acute corneal graft rejection, blepharitis, herpetic stromal keratitis, conjunctival graft versus host disease [GVHD]); AND
  - Patient has tried and failed (e.g., intolerance or inadequate response) Xiidra after at least 3 months of therapy unless there is clinical evidence or patient history that suggests the use of Xiidra will be ineffective or cause an adverse reaction to the patient.
  (Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

- Requested drug is Tyrvaya:
  - Patient has a diagnosis of symptomatic dry eye disease; AND
  - Patient is greater than or equal to 18 years of age; AND
  - Patient has tried and failed (e.g., intolerance or inadequate response) Xiidra after at least 3 months of therapy unless there is clinical evidence or patient history that suggests the use of Xiidra will be ineffective or cause an adverse reaction to the patient.
  (Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Restasis (cyclosporine ophthalmic emulsion), cyclosporine ophthalmic emulsion, Restasis Multidose (cyclosporine ophthalmic emulsion), Cequa (cyclosporine ophthalmic solution), or Tyrvaya (varenicline nasal spray) when the patient has not tried and failed Xiidra after at least 3 months of therapy to be not medically necessary.**
Topical Treatments for Dry Eye Disease

Policy #  00640  
Original Effective Date:  01/01/2019  
Current Effective Date:  08/14/2023

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of Restasis (cyclosporine ophthalmic emulsion), cyclosporine ophthalmic emulsion, Restasis Multidose (cyclosporine ophthalmic emulsion), Cequa (cyclosporine ophthalmic solution), or Tyrvaya (varenicline nasal spray) when the patient selection criteria are not met (other than those considered to be not medically necessary**) to be investigational.*

Background/Overview

The Restasis products (brand Restasis, generic cyclosporine ophthalmic emulsion, and Restasis Multidose) and Cequa contain the active ingredient, cyclosporine, and are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Cequa is a novel formulation of cyclosporine in which the hydrophobic cyclosporine molecules are encased in nanomicelles to facilitate the crossing of the corneal barrier. However, no head to head studies have been conducted to establish any benefit of Cequa over Restasis. In pivotal studies of Restasis, increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. Both products are dosed one drop twice a day in each eye (approximately 12 hours apart).

Tyrvaya is a nasal spray containing the active ingredient, varenicline, and is indicated for the treatment of the signs and symptoms of dry eye disease. It should be dosed as one spray in each nostril twice daily (approximately 12 hours apart). Clinical practice guidelines have not been updated to include Tyrvaya and head to head studies have not been conducted comparing it to ophthalmic products for dry eye disease.

Even though dry eye diseases due to systemic inflammatory disease or ocular surface diseases are not technically FDA approved indications for these products, the American Academy of Ophthalmology gives recommendations for Restasis in these conditions. Other options for the treatment of dry eye diseases include Xiidra (lifitegrast ophthalmic) and artificial tears. Guidelines have not been updated since Xiidra and Cequa received FDA approval.
Topical Treatments for Dry Eye Disease

Policy # 00640
Original Effective Date: 01/01/2019
Current Effective Date: 08/14/2023

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Restasis was approved in 2003 and is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

Cequa was approved in 2018 and is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Tyrvaya was approved in 2021 and is indicated for the treatment of the signs and symptoms of dry eye disease.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The patient selection criteria presented in this policy take into consideration clinical evidence or patient history that suggests the alternative treatment agent for dry eye disease, Xiidra (lifitegrast ophthalmic), is contraindicated, ineffective, or will cause an adverse reaction to the patient. Based on review of the data, if these factors are not present, there is no advantage of using the Restasis products or Cequa over Xiidra.

Although Tyrvaya has a novel mechanism of action and route of administration, it has not been compared in randomized controlled trials to other therapies for the treatment of dry eye disease. It also has not been incorporated into nationally recognized clinical practice guidelines. The patient selection criteria presented in this policy take into consideration clinical evidence that suggests the alternative treatment agent for dry eye disease, Xiidra, is contraindicated, ineffective, or will cause adverse reaction to the patient. Based on review of the data, if these factors are not present, there is no advantage of using Tyrvaya over Xiidra.
Topical Treatments for Dry Eye Disease

Policy #  00640
Original Effective Date:  01/01/2019
Current Effective Date:  08/14/2023

References

Policy History
Original Effective Date:  01/01/2019
Current Effective Date:  08/14/2023
10/04/2018  Medical Policy Committee review
06/06/2019  Medical Policy Committee review
06/19/2019  Medical Policy Implementation Committee approval. Added new drug, Cequa, to policy with relevant background information.
06/04/2020  Medical Policy Committee review
06/10/2020  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/04/2020  Medical Policy Committee review
06/10/2020  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/03/2021  Medical Policy Committee review
06/09/2021  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/03/2022  Medical Policy Committee review
02/09/2022  Medical Policy Implementation Committee approval. Changed title from Restasis, Cequa (cyclosporine ophthalmic) to “Topical Treatments for Dry Eye Disease.” Added new drug, Tyrvaya, with relevant criteria and background information.
07/07/2022  Medical Policy Committee review
07/13/2022  Medical Policy Implementation Committee approval. Added Restasis generic to policy.
07/06/2023  Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Topical Treatments for Dry Eye Disease

Policy # 00640
Original Effective Date: 01/01/2019
Current Effective Date: 08/14/2023

07/12/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
Next Scheduled Review Date: 07/2024

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.
Topical Treatments for Dry Eye Disease

Policy #  00640
Original Effective Date:  01/01/2019
Current Effective Date:  08/14/2023

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.